A repeat Lp(a) measurement may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial test result is in the intermediate ‘grey-zone’ as defined by the European Atherosclerosis Society guidelines.1,2
AstraZeneca has provided a sponsorship grant towards this independent programme.